Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions

7-Methoxypentacyclo[5.4.0.02,6.03,10.05,9]undecane-8,11-dione

The crystal structure of a meth­oxy-substituted Cookson’s dione derivative is presented.

The structure of 7-meth­oxy­penta­cyclo­[5.4.0.0^2,6.0^3,10.0^5,9]undecane-8,11-dione, C₁₂H₁₂O₃, at 150 K has monoclinic (P2₁/c) symmetry. The penta­cyclo­undecane cage compound is composed of four five-membered rings, a planar four-membered ring and a six-membered ring in a boat conformation fused into a closed strained-cage framework. All of the five-membered rings adopt an envelope conformation.

A new skeletal rearrangement of 1,7-dimethyl Cookson's cage dione catalyzed by a Lewis acid

A methyl-substituted polycyclic cage dione containing the PCUD framework has undergone an unprecedented ring rearrangement approach. Here, the PCUD framework with the aid of a Lewis acid such as BF3·MeOH gave unusual fragmentation products. Two new products were isolated via the skeletal rearrangement process involving carbocation mediated intermediates. The substituents in the succinyl bond present in the strained PCUD skeleton produce a driving force for the rearrangement in an unprecedented manner. Interestingly, the cyclobutane ring was transformed to cyclopentane through the cleavage of the C1-C7 bond during the ring-expansion process of PCUD via the carbocation intermediates. Unexpectedly, solvent (benzene) was captured during the ring-homologation process due to the presence of methyl substituents placed at the cyclobutane ring of the cage framework. It appears that this is the first report where an unexpected ring-rearrangement, ring-homologation, and ring-fragmentation occur with the aid of the BF3·MeOH complex.

Molecular Acrobatics in Polycyclic Frames: Synthesis of Functionalized D3-Trishomocubanes via the Rearrangement Approach

A new synthetic route to D₃-trishomocubanone and oxa- D₃-trishomocubane derivatives has been established by the rearrangement approach. A remotely located methyl substituent in the six-membered ring contributed to the acid-catalyzed rearrangement of the cage dione in an unusual fashion. This rearrangement approach provided an attractive route to extended D₃-trishomocubanes, which are not accessible by the conventional multistep synthetic sequence. For the first time, two phenyl groups were incorporated from the solvent into the strained trishomocubane skeleton in an unprecedented manner via carbocation-mediated rearrangement with the aid of BF₃·OEt₂. Interestingly, an oxa-bridged trishomocubane skeleton was also formed during acid-promoted rearrangement.

Role of Sigma-1 Receptor in Cocaine Abuse and Neurodegenerative Disease

Sigma-1 receptors (Sig-1R) are recognized as a unique class of non-G protein-coupled intracellular protein. Sig-1R binds to its ligand such as cocaine , resulting in dissociation of Sig-1R from mitochondrion-associated ER membrane (MAM) to the endoplasmic reticulum (ER), plasma membrane, and nuclear membrane, regulating function of various proteins. Sig-1R has diverse roles in both physiological as well as in pathogenic processes. The disruption of Sig-1R pathways has been implicated as causative mechanism(s) in the development of both neurodegenerative disorders such as Alzheimer disease (AD ), Parkinson disease (PD ), amyotrophic lateral sclerosis (ALS ) and Huntington Disease (HD ) . Additionally, the interaction of cocaine and Sig-1R has more recently been implicated in potentiating the pathogenesis of HIV-associated neurocognitive disorders (HAND) through impairment of blood-brain barrier (BBB), microglial activation and astrogliosis. On the other hand, restoration of Sig-1R homeostasis has been shown to exert neuroprotective effects. In this review, we provide an overview of how Sig-1R plays a role in the pathogenesis of neurodegenerative disorders and cocaine and implications for future development of therapeutic strategies.

Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs

Polycyclic cage scaffolds have been successfully used in the development of numerous lead compounds demonstrating activity in the central nervous system (CNS). Several neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, and stroke, as well as drug abuse, can be modulated with polycyclic cage derivatives. These cage moieties, including adamantane and pentacycloundecane derivatives, improve the pharmacokinetic and pharmacodynamic properties of conjugated parent drugs and serve as an important scaffold in the design of therapeutically active agents for the treatment of neurological disorders. In this Minireview, we focus on the recent developments in the field of polycyclic cage compounds, as well as the relationship between the lipophilic character of these cage-derived drugs and the ability of such compounds to target and reach the CNS and improve the pharmacodynamic properties of compounds conjugated to it.